In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients
Open Access
- 1 November 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 44 (5) , 697-700
- https://doi.org/10.1093/jac/44.5.697
Abstract
In this report we compare the activity of two new antifungal agents, voriconazole (UK-109,496) and LY303366 with the activities of other antifungals including fluconazole, itraconazole, 5-fluorocytosine (5FC) and amphotericin B against 219 oral Candida spp. isolates from HIV-infected patients. We used the broth microdilution method following the guidelines of the NCCLS. The in-vitro activity of voriconazole (UK-109,496) (MIC90 0.12 mg/L) and LY303366 (CMI90 0.25 mg/L) against clinical isolates of Candida spp. was excellent and comparable with that of amphotericin B (MIC90 0.5 mg/L), and better than those of fluconazole (MIC90 ≥ 64 mg/L), itraconazole (MIC90 4 mg/L) and 5FC (MIC90 1 mg/L).Keywords
This publication has 5 references indexed in Scilit:
- In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates of Candida sppAntimicrobial Agents and Chemotherapy, 1998
- Echinocandins and pneumocandins--a new antifungal class with a novel mode of actionJournal of Antimicrobial Chemotherapy, 1997
- Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 1997
- Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemiaBritish Journal of Haematology, 1997
- In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolatesAntimicrobial Agents and Chemotherapy, 1997